Orasis Pharmaceuticals has secured approval in the US for its age-related blurry vision eye drops, marking the second time the FDA has greenlit a presbyopia treatment.
PONTE VEDRA, Fla. , April 23, 2022 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced Phase 2b data demonstrating the efficacy and safety of its novel eye drop candidate, CSF-1, for the treatment of presbyopia at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26 in Washington, D.C. The Phase 2b trial served as the foundation for the design and conduct of the Phase 3 NEAR-1 and NEAR-2 clinical trials of CSF-1, for which topline results were recently announced.
Orasis Pharmaceuticals probably doesn’t think it’s the underdog with the two Phase III results it has in hand for an eye drop meant to help people with age-related loss of near vision.
PONTE VEDRA, Fla., April 21, 2022 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced that the Phase 3 NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of CSF-1, its novel eye drop candidate, met their primary and key secondary endpoints. Additional details of these trials will be presented at future medical meetings and will serve as the basis for the New Drug Application submission to the U.S. Food and Drug Administration (FDA) in the second half of 2022.
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with...
HERZLIYA, Israel, March 15, 2022 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced the completion of its NEAR-1 and NEAR-2 Phase 3 clinical studies.